Genor Biopharma Holdings Limited (6998.HK)
HKD 1.66
(-5.68%)
HKD 1.66
(-5.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -425.12 Million | -577.6 Million | -623.74 Million | -786.71 Million | -110.52 Million | -253.39 Million |
| Net Income | -677.49 Million | -732.42 Million | -866.3 Million | -3.03 Billion | -523.63 Million | -288.07 Million |
| Depreciation & Amortization | 76.88 Million | 53.67 Million | 60.74 Million | 50.48 Million | 40.63 Million | 37.18 Million |
| Deferred income taxes | - | - | 79.79 Million | 184.3 Million | 1.01 Million | - |
| Stock-based compensation | 60.91 Million | 48.23 Million | 123.69 Million | 257.62 Million | 108.09 Million | 35.53 Million |
| Change in working capital | -5.49 Million | 79.55 Million | 28.68 Million | -218.24 Million | 261.28 Million | -43.25 Million |
| Other non-cash items | -33.81 Million | -26.65 Million | -50.35 Million | 1.97 Billion | 2.08 Million | 5.22 Million |
| Investing Cash Flow | 5.98 Million | -12.94 Million | -54.26 Million | -98.24 Million | -40.67 Million | -29.52 Million |
| Investments in PPE | -1.03 Million | -12.95 Million | -71.39 Million | -98.29 Million | -27.94 Million | -29.52 Million |
| Acquisitions | - | - | 24.92 Million | - | -12.73 Million | - |
| Investment purchases | - | - | -7.47 Billion | - | - | - |
| Sales/Maturities of investments | - | - | 7.48 Billion | - | - | - |
| Other Investing Activities | 7.02 Million | 15 Thousand | -24.3 Million | 49 Thousand | -7.35 Million | 4000.00 |
| Financing Cash Flow | -6.82 Million | -57.39 Million | 17.57 Million | 3.73 Billion | 278.54 Million | 346.93 Million |
| Debt repayment | -5.93 Million | -99 Million | -34.5 Million | -18.52 Million | -7.88 Million | -100.9 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -5.13 Million | - | - | -574.39 Million | -1.01 Billion |
| Common Stock Issuance | 2000.00 | - | 2.72 Million | 2.73 Billion | 862.91 Million | 996.91 Million |
| Other Financing Activities | -886 Thousand | 46.74 Million | 49.35 Million | 1.02 Billion | 580.18 Million | -549.08 Million |
| Accounts receivables | 9.62 Million | - | - | -87.68 Million | 581 Thousand | 67 Thousand |
| Accounts payables | - | - | - | 87.68 Million | -581 Thousand | - |
| Inventory | 7.9 Million | -4.7 Million | -22.33 Million | -7.66 Million | -1.36 Million | 3.48 Million |
| Other working capital | -23.18 Million | 84.26 Million | 51.02 Million | -210.58 Million | 262.64 Million | -46.73 Million |
| Cash at beginning of period | 1.58 Billion | 2.2 Billion | 2.92 Billion | 253.52 Million | 125.15 Million | 61.1 Million |
| Cash at end of period | 1.16 Billion | 1.58 Billion | 2.2 Billion | 2.92 Billion | 253.52 Million | 125.15 Million |
| Capital Expenditure | -1.03 Million | -12.95 Million | -71.39 Million | -98.29 Million | -27.94 Million | -29.52 Million |
| Effect of forex changes on cash | 2.73 Million | 36 Million | -68.67 Million | -177.19 Million | 1.02 Million | 42 Thousand |
| Net cash flow / Change in cash | -423.22 Million | -611.93 Million | -729.1 Million | 2.67 Billion | 128.36 Million | 64.05 Million |
| Free Cash Flow | -426.15 Million | -590.56 Million | -695.13 Million | -885 Million | -138.47 Million | -282.91 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -62.84 Million | -62.84 Million | -677.49 Million | -199.9 Million | -199.9 Million | -137.27 Million |
| Depreciation & Amortization | - | - | 76.88 Million | 24.57 Million | 22.22 Million | 13.87 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.45 Million | 2.45 Million | 60.91 Million | 11.88 Million | 11.88 Million | 18.56 Million |
| Change in working capital | - | - | -5.49 Million | -7.63 Million | -7.63 Million | - |
| Other non-cash items | 60.39 Million | 60.39 Million | -33.81 Million | 73.87 Million | 76.21 Million | -10.51 Million |
| Investing Cash Flow | - | - | 5.98 Million | 2.51 Million | 2.51 Million | 477.5 Thousand |
| Investments in PPE | - | - | -1.03 Million | 376 Thousand | 376 Thousand | -893 Thousand |
| Acquisitions | - | - | - | - | - | 3.09 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 7.02 Million | 2.14 Million | 2.14 Million | 1.37 Million |
| Financing Cash Flow | - | - | -6.82 Million | -1.53 Million | -1.53 Million | -1.88 Million |
| Debt repayment | - | - | -5.93 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 2000.00 | - | - | - |
| Other Financing Activities | - | - | -886 Thousand | -1.53 Million | -1.53 Million | -1.88 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 7.9 Million | 3.95 Million | 3.95 Million | - |
| Other working capital | - | - | -23.18 Million | -11.59 Million | -11.59 Million | - |
| Cash at beginning of period | - | - | 1.58 Billion | - | - | 1.78 Billion |
| Cash at end of period | - | - | 1.16 Billion | -98.24 Million | -98.24 Million | 1.46 Billion |
| Capital Expenditure | - | - | -1.03 Million | 376 Thousand | 376 Thousand | -893 Thousand |
| Effect of forex changes on cash | - | - | 2.73 Million | -2.01 Million | -2.01 Million | 3.38 Million |
| Net cash flow / Change in cash | - | - | -423.22 Million | -98.24 Million | -98.24 Million | -314.38 Million |
| Free Cash Flow | - | - | -426.15 Million | -96.83 Million | -96.83 Million | -116.23 Million |
EVTZF
AXISCADES
SOUTHERNIN
GLENMARK
ACOGF
STEL